What happened with MDT today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Medtronic supplies devices that physicians use to treat disease, perform surgery and monitor patients. Cardiovascular is its largest revenue business, with products such as implanted heart-rhythm devices, replacement heart valves and vascular treatments. Neuroscience supplies spinal implants and tools for brain and spine surgery, while Medical Surgical supplies surgical instruments, patient monitors and airway-management products. Together, these businesses generate most of its revenue.
Hospitals and other healthcare providers buy its products directly or through distributors. Medtronic also negotiates supply contracts with purchasing groups and healthcare networks for their member facilities. No single customer dominates sales, but purchasing depends on physicians choosing its devices and providers obtaining reimbursement from government or private payors. Regulatory approvals and manufacturing requirements constrain which products it can sell, and it cannot promote devices beyond their approved labeling.
Medtronic is separating its diabetes business into MiniMed, which sells insulin pumps, glucose-monitoring systems and consumables, including the MiniMed 780G automated insulin-delivery system. MiniMed is now publicly listed, but Medtronic still owns a large majority; further separation remains unfinished.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Boston Scientific challenges Medtronic across cardiovascular interventions and devices for neurological, digestive and urological conditions. Its cardiovascular-device business is one place to watch competition facing Medtronic’s heart and vascular therapies.
Abbott competes with Medtronic across devices that manage heart rhythms, treat vascular disease, replace heart valves, stimulate nerves and monitor glucose. That makes Abbott a rival spanning several Medtronic therapy businesses rather than just one product market.
Stryker competes with Medtronic for hospitals’ and specialist surgeons’ purchases of surgical instruments and devices used in brain blood vessels. Watch its instruments and neurovascular products rather than treating its orthopaedic business as a direct comparison.
Johnson & Johnson’s MedTech business competes with Medtronic in surgical instruments, neurovascular devices, surgical staplers and instruments that use energy during surgery. Its stapling and energy products are the relevant competition for Medtronic’s surgical business, not its prescription medicines.
Edwards Lifesciences competes with Medtronic in aortic valves delivered through a catheter and surgically implanted heart valves, but also pays Medtronic structural-heart royalties. Net sales of certain Edwards products determine those annual payments, so those sales matter to Medtronic beyond the rivalry.
Globus Medical competes with Medtronic in spinal implants, biologics and systems that image, navigate and robotically guide surgery. Its imaging, navigation and robotics business is a useful place to watch competition facing Medtronic’s spine-surgery technology.
Intuitive Surgical competes with Medtronic for hospitals’ surgical business through stapling, energy instruments and robotic-assisted procedure technology. Watch its da Vinci stapling and energy products, which extend into areas served by Medtronic’s conventional surgical instruments.
MiniMed Group, Inc. holds Medtronic’s separating diabetes business, and Medtronic’s approximately 90% retained ownership keeps it exposed to MiniMed’s performance and separation costs. Watch sales of insulin pumps, glucose sensors and supplies, alongside the cost of replacing functions Medtronic still provides during the transition.
BD competes with Medtronic in peripheral and cardiac interventions and surgical supplies sold to hospitals. Its interventional products and surgical consumables are the relevant businesses to watch for competition facing Medtronic, rather than its laboratory products.
Penumbra competes with Medtronic for specialist physicians’ use of brain and peripheral vascular devices that remove clots, block vessels or provide access to them. Its clot-removal, or thrombectomy, products for ischemic stroke are a concrete place to watch competition facing Medtronic’s stroke therapies.
Dexcom’s glucose sensors compete with those of MiniMed, Medtronic’s majority-owned diabetes business, so the rivalry still matters to Medtronic. Watch sensors used with pumps that automatically deliver insulin, where glucose monitoring and insulin delivery compete as an integrated system.
Insulet’s Omnipod insulin-delivery systems compete for insulin-dependent diabetes users with pumps sold by MiniMed, which Medtronic majority-owns. Watch acceptance of Omnipod’s tubeless disposable pods as an alternative to conventional pumps.
CONMED competes with Medtronic in powered surgical instruments, instruments that use energy during surgery, endoscopic products and patient monitors. Its general-surgery sales offer a view of the business overlapping Medtronic’s surgical and monitoring products.
Merit Medical competes with Medtronic in cardiac and peripheral interventions, spine products, and gastrointestinal and pulmonary devices. Watch its peripheral and cardiac intervention sales for competition facing Medtronic’s vascular products.
LivaNova competes with Medtronic in equipment used during cardiopulmonary surgery and implanted devices that stimulate nerves to treat epilepsy. Watch its vagus nerve stimulation therapy for drug-resistant epilepsy, a competing option to Medtronic’s implanted brain stimulation.
Teleflex competes with Medtronic for hospitals’ and interventional specialists’ purchases of cardiac and peripheral intervention devices. Its news on those products is more relevant to Medtronic’s vascular business than its broader range of single-use medical supplies.
Alphatec competes with Medtronic for spine surgeons’ use of implants, fixation systems, biologics and procedural technology. Watch surgeon adoption of its approach-specific procedures, which Alphatec identifies as a driver of future growth.
Artivion competes with Medtronic in mechanical heart valves and aortic stent grafts used to treat valve and aortic disease. Watch its On-X aortic valve’s labeling allowing reduced anticoagulation, a feature Artivion uses to compete; that approval does not cover mechanical mitral valves.
Integer is exposed to production demand in the cardiovascular and neuromodulation markets that also drive Medtronic, making devices and components for large medical-device companies rather than selling therapies to care providers. Its Cardiac Rhythm Management & Neuromodulation revenue offers a view of manufacturing demand in those markets, not proof of a supply relationship with Medtronic.
Boston Scientific Corp. earningsBSX
Boston Scientific's report will show how demand is moving for cardiovascular devices that compete with Medtronic's heart and vascular therapies.
Focus on Boston Scientific's cardiovascular-device business. Strong results would show support for demand in a market the companies share, where Medtronic still has to win hospital and specialist purchases. Weak results would suggest softer demand, not prove that Medtronic has gained share. The report is a read on the market, not a direct measure of Medtronic's sales.
CONMED Corporation earningsCNMD
CONMED's report will show hospital demand for general-surgery instruments and endoscopic products that overlap with Medtronic's surgical business.
Look at CONMED's general-surgery results, which are closer to the overlapping instrument and endoscopy business than its company-wide figures. Strong results would point to firm hospital demand and continued competition for Medtronic in those products. Weak results would suggest softer purchasing, not that Medtronic won the orders. The takeaway is the health of the shared market, not a change in market share.
Fed Interest Rate Decision
Medtronic’s $28.0 billion of debt makes the Fed’s decision on short-term borrowing rates relevant to what it pays when debt reprices or is refinanced.
Expected4.0%Last release4.0%
If it comes in above expectations
Higher rates could raise Medtronic’s interest costs on debt that reprices or on new borrowing to refinance maturing debt, leaving less cash for operations and other needs.
If it comes in below expectations
Lower rates could reduce Medtronic’s interest costs on debt that reprices or on new borrowing to refinance maturing debt, leaving more cash for operations and other needs.
DexCom, Inc. earningsDXCM
Dexcom's report will show demand for glucose sensors that compete in the integrated sensor-and-pump market with systems sold by Medtronic's majority-owned MiniMed.
Read Dexcom's sensor results in the context of systems that pair glucose monitoring with insulin delivery. Strong results would show active monitoring demand and a capable rival for MiniMed; weak results would offer less evidence of competitive pressure, not prove MiniMed is adding users. The takeaway is the state of the sensor market and rivalry, not a direct change in MiniMed sales.
Edwards Lifesciences Corp earningsEW
Edwards Lifesciences' report will show how sales are moving for certain heart-valve products that both compete with Medtronic and generate royalties for it.
Focus on sales of the Edwards products linked to Medtronic's royalties, not just Edwards' total sales. Strong sales would show demand in a shared valve market and support Medtronic's related royalty income; weak sales would weaken both signals. The key is performance of those specific products, not Edwards' business as a whole.
Penumbra, Inc. earningsPEN
Penumbra's report will show how demand is moving for its ischemic-stroke clot-removal devices, which compete with Medtronic's stroke therapies.
Focus on Penumbra's thrombectomy products, particularly those used for ischemic stroke. Strong results would show support for demand for these procedures and devices, and continued competition for Medtronic in stroke care. Weak results would suggest softer demand, not prove that Medtronic won cases or orders. The report is a signal about the shared treatment market, not a direct measure of Medtronic's share.
Insulet Corporation earningsPODD
Insulet's report will show demand for its tubeless Omnipod insulin-delivery system, which competes for users with pumps sold by Medtronic's majority-owned MiniMed.
Read Omnipod sales and adoption together. Strong results would show the tubeless format drawing users and give MiniMed's conventional pumps a stronger alternative to contend with; weak results would mean less evidence that this format is winning users. The report speaks to MiniMed's competitive setting, not Medtronic's own sales.
GLOBUS MEDICAL INC earningsGMED
Globus Medical's report will show surgeon adoption of its spine-surgery imaging, navigation and robotic systems, which compete with Medtronic's surgical technology.
Focus on Globus Medical's imaging, navigation and robotics results. Strong results would show surgeons adopting those spine technologies, increasing competition for Medtronic in the same operating rooms. Weak results would indicate less evidence of rival progress. This is a signal about competition in surgical technology, not a direct read on Medtronic's spine-implant sales.
Medtronic plc earningsThis company
Medtronic's report will show whether sales growth in its Cardiovascular, Neuroscience and Medical Surgical businesses is turning into higher segment operating profit.
Read sales alongside segment operating profit for Cardiovascular, Neuroscience and Medical Surgical. If both rise across all three, demand is broad and is converting into profit. If growth is concentrated in one or two, or profit lags sales, the improvement is less widespread and costs or pricing may be weighing on it.
MiniMed Group, Inc. earningsMMED
MiniMed's report will show how the diabetes business Medtronic still majority-owns is selling, alongside the cost of services Medtronic continues to provide during the transition.
Read MiniMed's sales of insulin pumps, glucose sensors and supplies alongside the cost of transition services Medtronic still provides. Supported sales with manageable costs would show that Medtronic's retained stake has an operating business behind it; weaker sales or rising costs would make the balance between that exposure and the separation burden less favorable. The question is whether the retained business is holding up against the costs of separating it.
